• 1
    IARC Monograph on the Evaluation of Carcinogenic Risks to Humans. Vol 64. Human papillomaviruses. Lyon, France: IARC Science Publishers, 1995.
  • 2
    Wallin KL, Wiklund F, Angstrom T, Bergman F, Stendahl U, Wadell G, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999; 34: 16338.
  • 3
    Schiffman M, Adrianza E, for the ALTS Group. The ASCUS-LSIL Triage Study (ALTS): design, methods, and characteristics of trial participants. Acta Cytol 2000; 44: 72642.
  • 4
    Jenkins D, Sherlaw-Johnson C, Gallivan S. Can papilloma virus testing be used to improve cervical cancer screening? Int J Cancer 1996; 65: 76873.
  • 5
    Cuzick J, Sasieni P, Davies P, Adams J, Normand C, Frater A, et al. A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions. Br J Cancer 2000; 83: 5615.
  • 6
    Elfgren K, Kalantari M, Moberger B, Hagmar B, Dillner J. A population-based five-year follow-up study of cervical human papillomavirus infection. Am J Obstet Gynecol 2000; 183: 5617.
  • 7
    Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M. Human papillomavirus type 16 in cervical smears as predictor of high-grade cervical intraepithelial neoplasia. Lancet 1992; 339: 95960.
  • 8
    Cox JT, Lorincz AT, Schiffman MH, Sherman ME, Kurman RJ, Hussein M, et al. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 1995; 172: 94654.
  • 9
    Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papnaicolaou results. J Am Med Assoc 1999: 281: 16457.
  • 10
    Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, et al. Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women. Br J Cancer 1999; 80: 130611.
  • 11
    Schneider A, Zahm DM, Kirchmayr R, Schneider VL. Screening for cervical intraepithelial neoplasia grade 2/3: validity of cytology study, cervicography, and human papillomavirus detection. Am J Obstet Gynecol 1996; 174: 153441.
  • 12
    Bergeron C, Jeannel D, Poveda J, Cassonet P, Orth G. Human papillomavirus testing in women with mild cytologic atypia. Obstet Gynecol 2000; 95: 8217.
  • 13
    Solomon D, Schiffman M, Tarone R for the ALTS Group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001; 93: 2939.
  • 14
    Kurman RJ, Solomon D. Bethesda System for reporting cervical/vaginal cytologic diagnoses. New York: Springer-Verlag, 1994.
  • 15
    Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. J Am Med Assoc 1994; 271: 18669.
  • 16
    Smith A, Sherman ME, Scott DR, Tabbara SO, Dworkin L, Olson J, et al. Review of the Bethesda System Atlas does not improve reproducibility or accuracy in the classification of atypical squamous cells of undetermined significance. Cancer Cytopathol 2000; 90: 2016.
  • 17
    Sherman ME, Schiffman MH, Lorincz AT, Manos MM, Scott DR, Kurman RJ, et al. Towards objective quality assurance in cervical cytopathology: correlation of cytopathologic diagnoses with detection of high-risk human papillomavirus types. Am J Clin Pathol 1994; 102: 1827.
  • 18
    Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993; 85: 95864.
  • 19
    Liaw KL, Glass AG, Manos MM, Greer C, Scott DR, Sherman ME, et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst 1999; 91: 95460.
  • 20
    Sherman ME, Schiffman MH, Mango LJ, Kelly D, Acosta D, Cason Z, et al. Evaluation of PAPNET testing as an ancillary tool to clarify the status of the “atypical” cervical smear. Mod Pathol 1997; 10: 56471.
  • 21
    Koss LG. Dysplasia: a real concept or a misnomer? Obstet Gynecol 1978; 51: 3749.
  • 22
    Richart RM, Barron BA. A follow-up study of patients with cervical dysplasia. Am J Obstet Gynecol 1969; 105: 38693.
  • 23
    Hildesheim A, Schiffman MH, Gravitt P, Glass AG, Greer C, Zhang T, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women in Portland, Oregon. J Infect Dis 1994; 169: 23540.
  • 24
    Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley and Sons, 1981: 21835.
  • 25
    Landis JR, Koch GG. The measurement of observer agreement for categorical and data. Biometrics 1977; 33: 15974.
  • 26
    Stoler MH, Schiffman M, for the ALTS Group. Inter-observer reproducibility of cervical cytologic and histologic diagnoses: realistic estimates from the ASCUS-LSIL Triage Study (ALTS). J Am Med Assoc 2001; 285: 15005.
  • 27
    The ALTS Group. HPV testing as a triage strategy for women with cytologic evidence of low grade squamous intraepithelial lesions: early results from a randomized trial on the clinical management of ASCUS and LSIL cytologic abnormalities. J Natl Cancer Inst 2000; 92: 397402.
  • 28
    Kjellberg L, Wiklund F, Sjoberg I, Wadell G, Angstrom T, Dillner J, et al. A population-based study of human papillomavirus deoxyribonucleic acid testing for predicting cervical intraepithelial neoplasia. Am J Obstet Gynecol 1998; 179: 1497502.